Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors.
To determine the rate of true tuberculin skin test (TST) response in a cohort of patients with rheumatic disease treated with tumor necrosis factor inhibitors (TNFi). The study population included consecutive patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA) treated with TNFi for at least 3 months. Patients with a positive TST at screening who began Tb prophylaxis before the beginning of TNFi therapy were excluded. All patients underwent a second TST. True TST response was defined as an increase of 6 mm of induration between the screening test and the second test. Forty patients (12 men and 28 women) were included. Mean age was 51.2 years. Of them, 27 (67.5%) had RA, eight (20%) had PsA, and five patients (12.5%) had AS. At pre-treatment TST, 15 patients had a TST > or = 5 mm. A significantly higher percent of patients with TST > or = 5 mm was seen among men compared with women (75% vs. 21%, p = 0.012) and patients with PsA compared with patients with RA (75% vs. 22%, p = 0.014). At the second test, eight (20%) had an increase of 6 mm between readings with four having an increase of 10 mm or more. Four patients received infliximab and the other four were treated with etanercept. Seven of these eight patients had RA and one was a patient with PsA. Patients with true TST response were significantly older and non-smokers with elevated sedimentation rate and a higher rate of anemia. Nationality, comorbid conditions, treatment with immunosuppressives, and BCG vaccination status had no significant influence on the TST response. Serial TST testing in patients receiving TNFi is indicated to identify patients with reactivation of latent tuberculosis infection or those exposed to mycobacterium.
Fuchs
Inbal
I
Department of Family Medicine, Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel.
Avnon
Lone
L
Freud
Tamar
T
Abu-Shakra
Mahmoud
M
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D015331:Cohort Studies; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D015994:Incidence; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012307:Risk Factors; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D014374:Tuberculin Test; D014376:Tuberculosis / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000995:Antitubercular Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept
J Immunol. 1999 Mar 15;162(6):3504-11
10092807
Arthritis Rheum. 2007 Jun 15;57(5):756-61
17530674
Immunity. 1995 Jun;2(6):561-72
7540941
Rheumatology (Oxford). 2007 Jun;46(6):1035-6
17409126
Ann Rheum Dis. 2006 May;65(5):699
16611876
Ann Rheum Dis. 2001 Feb;60(2):133-9
11156546
Harefuah. 2007 Mar;146(3):235-7, 244
17460934
Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 2):S221-47
10764341
Ann Rheum Dis. 2003 Dec;62(12):1241-2
14644871
Harefuah. 2007 Mar;146(3):212-8, 245
17460930
N Engl J Med. 2001 Oct 11;345(15):1098-104
11596589
Am J Respir Crit Care Med. 1999 Jan;159(1):15-21
9872812
Lancet. 2000 Sep 23;356(9235):1099-104
11009160
J Rheumatol. 2007 Mar;34(3):474-80
17299840
Thorax. 2002 Sep;57(9):804-9
12200526
Ann Rheum Dis. 2005 Sep;64(9):1360-1
16100342
MMWR Recomm Rep. 2005 Dec 16;54(RR-15):49-55
16357824
Clin Gastroenterol Hepatol. 2004 Apr;2(4):309-13
15067625
Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1419-22
11029355
MMWR Recomm Rep. 2003 Jan 31;52(RR-2):15-8
12583541
Lancet. 2006 Apr 22;367(9519):1328-34
16631911